Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas

NCT05013515 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Salivary Gland Carcinomas

Interventions

DRUG: Surufatinib

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University